Gastric cancer is the World's second most common cause of cancer death. We analyzed gene expression patterns in 90 primary gastric cancers, 14 metastatic gastric cancers and 22 non-neoplastic gastric tissues, using cDNA microarrays representing approximately 30,300 genes. Gastric cancers were distinguished from non-neoplastic gastric tissues by characteristic differences in their gene expression patterns. We found a diversity of gene expression patterns in gastric cancer, reflecting variation in intrinsic properties of tumor and normal cells and variation in the cellular composition of these complex tissues. We identified several genes whose expression levels were significantly correlated with patient survival. The variations in gene expression patterns among cancers in different patients suggest differences in pathogenetic pathways and potential therapeutic strategies.
INTRODUCTION
Gastric cancer is the second most common cause of cancer death worldwide (Parkin et al., 1999) . Environmental and genetic factors are both important in gastric carcinogenesis. Gastritis, most commonly due to Helicobacter pylori (H. pylori) infection, is strongly associated with development of gastric cancer (Parsonnet et al., 1991) . In a small fraction of gastric cancers, the cancer cells have been found to be latently infected by Epstein-Barr virus (Shibata and Weiss, 1992) . Intestinal metaplasia in response to chronic inflammation often precedes development of gastric cancer, and may be an important precursor (Correa, 1988) . The Lauren classification, which distinguishes tumors based on their histological appearance into "intestinal" and "diffuse" types, has proven to be clinically useful (Lauren, 1965) . These two histological types have been proposed to be related to differences in pathogenetic mechanisms (Lauren, 1965; Grabiec and Owen, 1985) .
The prognosis of gastric cancer depends heavily on tumor stage at diagnosis. Surgical resection, still the mainstay of treatment, is very effective in early stage cancer. However, most patients present in advanced stages, however, when the prognosis is extremely poor.
Recent studies have shown that comprehensive analysis of gene expression patterns can identify new molecular criteria for classification and prognostication of diverse cancers (Dhanasekaran et al., 2001; Garber et al., 2001; Sorlie et al., 2001; van 't Veer et al., 2002) . The molecular portraits provided by the tumors' gene expression patterns provide a basis for recognizing new subtypes of cancer that, while morphologically indistinguishable, differ in clinical behavior, molecular pathways of tumor development, 4 and underlying genetic predisposition (Alizadeh et al., 2000; Perou et al., 2000; Hedenfalk et al., 2001; Rosenwald et al., 2001; Pomeroy et al., 2002; Rosenwald et al., 2002) .
Previous studies have reported expression profiles in small numbers of gastric cancer samples, identifying a few hundred genes that distinguish tumor from normal tissue (ElRifai et al., 2001; Hippo et al., 2002) . However, these studies were too small to distinguish subgroups or identify any genes whose expression may be correlated with clinical outcomes. Here we describe a systematic study of gene expression patterns in gastric adenocarcinomas and non-neoplastic gastric mucosa. The results define potential molecular criteria for disease classification, early detection and prognostication, as well as providing new insights into the pathogenesis and progression of gastric cancers.
MATERIALS AND METHODS

Samples and RNA preparation
Samples of tumor and normal gastric mucosa were collected from gastrectomy specimens from Dept. of Surgery, Queen Mary Hospital, The University of Hong Kong. Tissues were frozen in liquid nitrogen within half an hour after they were resected. Nonneoplastic mucosa from stomach, small intestine and colon was dissected free of muscle, and histologically confirmed to be tumor-free by frozen section. Total RNA was extracted using Trizol (Gibco BRL) and mRNA was isolated by the FastTrack mRNA isolation kit (Invitrogen). This study was approved by the Ethics Committee of the University of Hong Kong and the IRB from Stanford University.
Tumors were classified using the Lauren's classification into intestinal, diffuse, mixed and indeterminate types (Lauren, 1965) . The presence of H. pylori in the gastrectomy specimens was determined by histological examination, supplemented by Modified Giemsa staining. The presence of EBV in cancer cells was assayed by in-situ hybridization for EBER as described previously (Yuen et al., 1994) . The tumor stage was defined by the General Rules for Gastric Cancer Study of the Japanese Research Society for Gastric Cancer (Nishi M and editors, 1995) .
Microarray procedure and data analysis
We used cDNAs microarray containing 44,500 cDNA clones, representing about 30,300 unique genes. The methods for microarray production and hybridization, and data analysis, including hierarchical clustering, closely followed previously described procedures (Alizadeh et al., 2000; Perou et al., 2000) . In brief, 2 micrograms of sample mRNA and 2 micrograms of reference mRNA were used as template for synthesis of cDNA, labeled with Cy5-dUTP and Cy3-dUTP (Amersham) respectively, using Reverse Transcriptase (GibcoBRL) for 2 hours at 42 o C. The two labeled cDNA samples were separated from unincorporated nucleotides by filtration, mixed and hybridized to microarray at 65 o C overnight. After hybridization, each microarray was washed with 2xSSC, 0.03%SDS for 5 minutes at 65 o C, then with 1xSSC for 5 minutes and 0.1xSSC
for 5 minutes, both at room temperature. The array was then scanned with a GenePix 6 4000B microarray scanner (Axon Instruments). Primary data collection and analysis were carried out using GenePix Pro 3.0 (Axon Instruments). Areas of the array with obvious blemishes were manually flagged and excluded from subsequent analysis. The raw data were deposited into Stanford Microarray Database at:
http://genome-www4.stanford.edu/MicroArray/SMD/index.html.
Statistical analysis
Prior to the statistical analysis, the missing values in the dataset were estimated by a KNN impute algorithm using 12 neighbors . A non-parametric t-test with p-value cutoff of 0.001 or 0.002 based on 10,000 random column permutations was used to identify genes differentially expressed in gastric cancer and non-neoplastic gastric tissue samples 
RESULTS AND DISCUSSION
Using a cDNA microarray containing 44,500 clones, representing approximately 30,300 different genes, we profiled mRNA populations in 90 primary gastric adenocarcinomas, lymph node metastases from 14 of the same 90 tumors, and 22 samples of non-neoplastic gastric mucosa adjacent from resected tumors, representing both antrum (12 samples) and body (10 samples). Among the 12 antral tissues, 7 showed intestinal metaplasia. From the roughly 30,000 genes whose expression was measured in these samples, we identified a set of approximately 5200 genes whose transcripts varied by at least 2.5 fold from their mean abundance in the sample set, in at least 3 samples ( Figure 1 ). We used a hierarchical clustering method to group these genes on the basis of similarity in expression across the samples, and to group samples based on similarity in their gene expression patterns.
Heterogeneity of the gene expression patterns among gastric cancer tissues
Simple hierarchical clustering analysis readily segregated non-tumor samples from all the tumors, and revealed complex variations in gene expression patterns among the gastric cancers. Eleven of the 14 lymph node metastases were clustered with primary tumor from which they arose, implying that the gene expression patterns in the metastatic tumor masses were more similar to the patterns in the corresponding primary tumors, than to any of the other metastatic or primary tumors. The three exceptions were attributable to differences between the primary and metastatic tumors in the admixture of non-tumor cells; when hierarchical clustering of the tumors was carried out based on expression of set of genes that excluded genes characteristically expressed in lymphocytes and stromal 8 cells, all fourteen pairs of primary and metastatic tumors from the same patient clustered together as nearest neighbors (see web supplement). This result implies that each gastric cancer has a unique characteristic gene expression pattern, and that the distinctive features of these molecular portraits are maintained even when tumors metastasize to the lymph node. We can use these 14 paired samples to identify a set of "intrinsic genes", whose expression levels vary widely among tumors from different patients, but are closely matched in primary and metastatic tumors from the same patient. These genes are likely to be especially useful for recognition of molecular subtypes of gastric cancer (Perou et al., 2000) (see web supplement).
Genes with consistent differences in expression between the gastric cancer and the nonneoplastic gastric tissues are of particular interest. Using a non-parametric t-test, we identified 2656 genes whose expression levels were significantly different between tumor and normal tissues, with p value less than or equal to 0.001, and a false discovery rate of 0.13% (see web supplement).
A cluster of approximately 2000 genes was expressed at higher levels in most of gastric cancers compared with non-tumor tissues (Figure 1 ). Among these 2000 genes were a group of genes associated with cell cycle progression, the "proliferation cluster" (Iyer et al., 1999; Whitfield et al., 2002) , whose transcripts were generally much more abundant in the tumors than in non-neoplastic tissues, though their levels varied considerably among the tumor samples ( Figure 2c ).
Several clusters of genes that appear to reflect primary events important for gastric carcinogenesis, such as chromosomal amplifications or alterations in transcriptional regulators or signal transduction pathways, were specifically associated with subsets of these cancers. For example, cyclinE1, POP4, RMP, UQCRFS1 and DKFZP762D096, were co-expressed at greatly elevated levels in about 10% of gastric tumors (Fig 2a) . All these genes are located on chromosome 19q12-13, suggesting amplification of a locus containing CyclinE1 in this group of tumors. Similarly, in about 10% of tumors, a cluster of genes including ErbB2 and two neighboring genes on chromosome 17q12-21 (Grb7 and MLN64), showed markedly elevated expression, strongly suggesting amplification of the ErbB2 locus in these tumors (Fig 2b) .
Another cluster of genes jointly expressed at elevated levels in some gastric cancers included AXIN2 and beta-catenin (Fig 2d) . AXIN2 is induced by beta-catenin/TCF as part of an auto-regulatory pathway in Wnt signaling. Colorectal and liver tumors with activation of the Wnt signaling pathway have been shown consistently to express a high level of AXIN2 (Lustig et al., 2002) . Activation of this pathway by mutations in APC or beta-catenin leads to increased levels of beta-catenin and its nuclear localization (Korinek et al., 1997) . Indeed, immunohistochemical staining revealed nuclear beta-catenin in many of the gastric tumors that express high levels of AXIN2 (see web supplement).
Abnormal activation of the Wnt pathway may therefore play a role in the pathogenesis of this distinct subgroup of gastric tumors. This gene cluster also included EphB2, a member of the Eph receptor tyrosine kinases. Ephrin signaling has been shown to be important in embryonic development, including axon guidance and angiogenesis (Kullander and Klein, 2002) . This pathway has also been implicated in promoting tumorgenesis (Dodelet and Pasquale, 2000) . A recent study showed that the activation of beta-catenin led to high expression of EphB receptors, and that expression of EphB is crucial for the correct positioning of epithelial cells in gut (Batlle et al., 2002) . It is therefore interesting to note that EphB2 co-clustered with beta-catenin and AXIN2
because of its patterns of expression in these gastric cancer tissues. The relationship of expression of EphB and Wnt signaling pathways in gastric cancer development deserves further investigation.
Clusters of genes that were generally more highly expressed in normal gastric mucosa than in gastric cancers are also of considerable interest (Figure 2e&f ). Among them, many are known to have role in the digestive function of the stomach or the integrity of the mucosa, such as pepsinogen C, carbonic anhydrase II, specific subtypes of gastric mucins (MUC5AC and MUC6) and somatostatin. Some putative tumor suppressor genes or genes with known growth inhibitory effects in the gastrointestinal tract can also be found in this cluster. These include TFF1 -mice lacking TFF1 develop gastric adenomas and intramucosal carcinomas (Lefebvre et al., 1996) ; and CDKN1C, the gene encoding the p57KIP2 cyclin-dependent kinase inhibitor, whose promoter has been found to be methylated, accompanied by transcriptional silencing, in some gastric cancer cell lines (Shin et al., 2000) .
Gastric cancer is a histologically complex tissue. The reciprocal interactions between tumor cells and stromal cells play important roles in tumor biology. A cluster of genes, including many that encode extracellular matrix components, appears to reflect variation in the proportion of stromal cells in the tumor. The genes in this cluster tend to be significantly more highly expressed in tumors of the "diffuse" histological type than in tumors of the "intestinal" type (see web supplement), consistent with greater propensity of this group of tumors for invasive growth, often provoking a dense fibrous reaction.
The expression patterns of two clusters of genes, which we term the "leukocyte" and "interferon" clusters, respectively, appear to reflect the density, composition and physiology of infiltrating leucocytes. The genes in these two clusters were generally significantly more highly expressed in the EBV-associated tumors (see web supplement), consistent with previous reports that these EBV-associated gastric cancers are often, though not invariably, accompanied by intense lymphoid infiltrate. A cluster of genes that included immunoglobulin genes was expressed at high levels in gastric mucosa and in some tumors, and their expression correlated well with the number of plasma cells as determined by histological examination (see web supplement). Similarly, a cluster enriched in genes characteristically expressed by smooth muscle appears to reflect adventitious smooth muscle cells in the samples (see web supplement).
A gene expression pattern associated with intestinal metaplasia defines a distinct subset of gastric cancers
Gastric cancers frequently arise in a background of chronic gastritis with intestinal metaplasia. As a step toward understanding this relationship, we explored the variations in gene expression patterns in different anatomical regions of the normal stomach, in metaplastic gastric mucosa, and in samples of normal mucosa from small intestine and colon (displayed to the right of the main cluster) (Figure 3 ). Based on their global gene expression patterns, the samples of non-neoplastic gastric mucosa were segregated into 3 branches, one corresponding to the gastric body and the other two corresponding to antral mucosa with and without intestinal metaplasia, respectively.
Three prominent gene clusters distinguished these three different types of gastric mucosa.
A group of genes were expressed selectively in gastric body, but not in antrum, small intestine or colon, nor, to any significant degree, in gastric tumors (Figure 3a) . This group included genes involved in transport (KCNJ16) and proteolysis (PSMB9), presumably reflecting functional specialization of the mucosa of the gastric body. A second cluster of genes, expressed at high level in metaplastic mucosa, but very little in non-metaplastic mucosa and most gastric tumors (Figure 3b ), included genes with roles in lipid (MTP, FABP1, APOA1), amino acid (GGT1) or glucose (ALDOB) transport or metabolism.
Most of these genes are also highly expressed in small intestine, and to a lesser extent in the colon. The third cluster of genes, also highly expressed in metaplastic antral mucosa compared with non-metaplastic gastric mucosa, appears to be related to the control of intestinal differentiation (Figure 3c ). Genes in this cluster include transcription factors that are involved in inducing and maintaining differentiation of the small and large intestine (CDX1, CDX2, and HNF4A); as well as integral membrane proteins and adhesion molecules that are characteristic of intestinal epithelium (CLDN3, CLDN4, CDH17, VIL1). The genes in this cluster are expressed in small intestine and colon mucosa, supporting their association with intestinal differentiation. Surprisingly, this group of genes was also expressed at high levels in many gastric cancers. On the basis of 13 expression of 41 genes in the cluster, the 90 gastric cancer samples can be segregated into two groups, which for the purpose of this discussion, we labeled "intestinal-like" and "gastric-like" (Figure 3d ). We hypothesized that tumors showing "intestinal-like" gene expression patterns were derived from gastric mucosa cells that have undergone intestinal metaplasia.
Gastric cancer is traditionally classified into two subtypes based on their histological architecture (Lauren, 1965) . The "intestinal type", characterized by cohesive growth of cells in quasi-glandular structures, has been presumed to arise secondarily from intestinal metaplasia, while the "diffuse type", in which tumor cells were dispersed and generally not organized into glandular structures, has been thought to arise directly from nonmetaplastic foveolar or mucous neck cells (Grabiec and Owen, 1985) . We therefore explored the relationship between expression of this intestinal differentiation gene cluster and the two histologically defined cancer subtypes. To our surprise, the "intestinal-like" gene expression pattern was seen with equal frequency in the histologically defined intestinal and diffuse groups (Figure 3d and web supplement). In contrast, there was a strong association between the "intestinal-like" gene expression pattern and the presence of intestinal metaplasia at the tumor edge (p<0.001) (Figure 3d and web supplement).
Our data therefore suggest the possibility that the "intestinal-like" gastric cancers, as defined based on their gene expression patterns, may arise from gastric mucosal cells that have previously undergone intestinal metaplasia and thus retain the molecular signature of the intestinal enterocyte; whereas the "gastric-like" cancers may arise by alternative pathway that does not involve intestinal metaplasia as an intermediate step. It will be important in following up these results, to focus for the attention on the progression of gastric events involved in metasplasia and gastric cancer development.
Our identification of a transcriptional program related to intestinal differentiation in gastric cancer provides one potential basis for extending classification of gastric cancer beyond morphological distinctions. Antibodies against proteins encoded by genes in the "intestinal differentiation" cluster may provide a convenient adjunct to conventional histopathology in classifying gastric cancers. Because the distinct molecular phenotypes of the "intestinal-like" and "gastric-like" gastric cancers are likely to have counterparts in the physiology and behavior of the tumors, recognition of these differences may be of significant value in evaluating clinical behavior and treatment trials.
Differential expression of the molecular targets of potential therapeutic agents
Specific features of the gene expression programs that distinguish gastric cancers may not only provide clues to differences in their regulation but may provide critical information for individualized therapy using molecularly targeted treatment modalities. For example, TACSTD1, which encodes a homophilic calcium-independent cell adhesion molecule, is among the genes characteristically expressed in the "intestinal-like" subset of gastric cancers. A monoclonal antibody (CO17-1A) against this protein has shown considerable promise in treatment of colorectal cancer in phase II/III randomized clinical trials (Riethmuller et al., 1998) . The differential expression of this gene among gastric cancers suggests its potential selective application in treatment of patients with "intestinal-like" gastric cancer. Similarly, the elevated expression of the EGF receptor in about 15% of gastric cancers suggests that these patients may benefit from compounds (both small molecular inhibitors and monoclonal antibodies) that target this protein, which have shown promise in clinical trials against a variety of cancers; and the highly elevated expression of ErbB2 in a small but significant fraction of gastric cancers raises the possibility that this group of patients may benefit from treatment with Herceptin.
Gene expression patterns and infectious etiologies
Despite the strong association between H. pylori infection and gastric cancer, we were unable to identify genes whose expression levels were significantly associated with H. The expression levels of 326 genes showed a significant association with EBV infection (p<=0.002, and FDR = 5%) (see web supplement). Some of these genes appeared to be related to the lymphoid infiltrate often observed in EBV+ gastric cancers. Among the 135 genes whose expression tended to be significantly higher in the EBV+ cancers was p53, consistent with previous reports of elevated p53 expression by a non-mutational mechanism in these tumors (Leung et al., 1998; Wu et al., 2000) . Interestingly, we found that most (11/12) EBV-associated gastric cancers had the "gastric-like" gene expression phenotype (p=0.007) (Figure 3d and web supplement), although most of these tumors would be classified as "intestinal" by histopathology. The role of EBV in the pathogenesis of this distinct type of gastric cancer will be an interesting question for future investigation.
Expression patterns significantly correlated with patient survival
We identified several genes whose expression levels in the gastric cancer samples were significantly associated with patient survival (see web supplement). These genes define molecular markers that may be immediately useful for prognosis and treatment stratification. Clearly, it will be important to corroborate the association between the expression of these genes, and patient survival in an independent sample set. Some of these genes may play important roles in gastric tumor progression. For example, a high level of expression of IGF-2 was associated with poor patient survival (p<0.002 by Cox regression assay). Overexpression of IGF-2 has been implicated in progression and metastasis of many types of cancers, including colon cancer, breast cancer, Wilm's tumor, and neuroblastoma (Toretsky and Helman, 1996) . The potential involvement of IGF-2 in the progression of gastric cancer clearly warrants further investigation. Patients whose gastric cancers expressed PLA2G2A, the gene encoding the group IIa secreted phospholipase A2, at high levels, had a highly significant survival advantage (p<0.002).
The murine ortholog of PLA2G2A, has been shown genetically to limit the severity of intestinal neoplasia in the Apc min1/+ mouse, a mouse model of familial adenomatous polyposis, suggesting that PLA2G2A may play a similar role in suppressing progression of human gastric cancer (MacPhee et al., 1995; Cormier et al., 1997) . A more extensive analysis and discussion of the association between PLA2G2A and gastric cancer progression is reported separately (Leung et al., 2002) .
In summary, a systematic study of gene expression patterns in human gastric cancers has revealed inherent molecular heterogeneity in gastric cancer, and identified multidimensional variations in gene expression patterns that distinguish gastric carcinoma and gastric mucosa in various pre-neoplastic stages. By using both supervised and unsupervised methods to search for relationships and systematic patterns in the data and by comparison of the expression patterns in the cancers with those seen in normal tissue of various histological types, we can begin to place features of this molecular variation into an interpretative framework that provides insights into the biological features and potential clues to the pathogenesis of these cancers. Differences among cancers in expression of specific genes may provide strong predictors of prognosis, and 
